WO2004005882A3 - Multi-parameter high throughput screening assays (mphts) - Google Patents
Multi-parameter high throughput screening assays (mphts) Download PDFInfo
- Publication number
- WO2004005882A3 WO2004005882A3 PCT/US2002/019457 US0219457W WO2004005882A3 WO 2004005882 A3 WO2004005882 A3 WO 2004005882A3 US 0219457 W US0219457 W US 0219457W WO 2004005882 A3 WO2004005882 A3 WO 2004005882A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mphts
- assays
- throughput screening
- high throughput
- screening assays
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002368043A AU2002368043A1 (en) | 2001-06-18 | 2002-06-18 | Multi-parameter high throughput screening assays (mphts) |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29915101P | 2001-06-18 | 2001-06-18 | |
US60/299,151 | 2001-06-18 | ||
US31782801P | 2001-09-07 | 2001-09-07 | |
US60/317,828 | 2001-09-07 | ||
US32515001P | 2001-09-25 | 2001-09-25 | |
US60/325,150 | 2001-09-25 | ||
US33304701P | 2001-11-14 | 2001-11-14 | |
US60/333,047 | 2001-11-14 | ||
US34993602P | 2002-01-18 | 2002-01-18 | |
US60/349,936 | 2002-01-18 | ||
US36183402P | 2002-03-04 | 2002-03-04 | |
US60/361,834 | 2002-03-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004005882A2 WO2004005882A2 (en) | 2004-01-15 |
WO2004005882A3 true WO2004005882A3 (en) | 2005-01-27 |
Family
ID=30119502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/019457 WO2004005882A2 (en) | 2001-06-18 | 2002-06-18 | Multi-parameter high throughput screening assays (mphts) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002368043A1 (en) |
WO (1) | WO2004005882A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DE102004016437A1 (en) * | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Method for detecting signatures in complex gene expression profiles |
EP1745144B1 (en) | 2004-05-11 | 2010-12-01 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
US7951542B2 (en) | 2009-11-04 | 2011-05-31 | Surgene, LLC | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7985551B2 (en) | 2009-11-04 | 2011-07-26 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7972793B2 (en) | 2009-11-04 | 2011-07-05 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7951543B2 (en) | 2009-11-04 | 2011-05-31 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
CN111826436B (en) * | 2020-07-21 | 2022-10-04 | 国家烟草质量监督检验中心 | Group high-throughput determination method for gene and corresponding protein expression change in hippocampal tissues in nicotine addiction, withdrawal and addiction reconstruction stages |
-
2002
- 2002-06-18 WO PCT/US2002/019457 patent/WO2004005882A2/en not_active Application Discontinuation
- 2002-06-18 AU AU2002368043A patent/AU2002368043A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
DATABASE GENBANK [online] XP002903971, accession no. NCBI Database accession no. M22357 * |
HAKAK ET AL.: "Genome-Wide Expression Analysis Reveals Dysregulation of Myelination-Related Genes in Chronic Schizophrenia", PNAS, vol. 98, no. 8, 2001, pages 4746 - 4751, XP002957625 * |
HAUGABOOK ET AL: "High Throughput Screens for the Identification of Compounds that Alter the Accumulation of the Alzheimer's Amyloid B Peptide (AB).", JOURNAL OF NEUROSCIENCE METHODS, vol. 108, 2001, pages 171 - 179, XP002958534 * |
SAUNDERS: "Gene Identification in Alzheimer's Disease.", PHARMACOGENOMICS, vol. 2, no. 3, 2001, pages 239 - 249, XP008040120 * |
SHOEMAKER ET AL: "Application of High Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery", CURRENT TROPICS IN MED. CHEM., vol. 2, no. 3, 2002, pages 229 - 246, XP002903970 * |
US NATIONAL OF MEDICINE: "Two Forms of 1B236/Myelin-Associated Glycoprotein, a Cell Adhesion Molecule for Postnatal Neural Development, are Produced by Alternative Splicing", PNAS, vol. 84, no. 12, 1987, BETHESDA, MARYLAND, USA, pages 4337 - 4341 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002368043A1 (en) | 2004-01-23 |
WO2004005882A2 (en) | 2004-01-15 |
AU2002368043A8 (en) | 2004-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003042654A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
GB0117326D0 (en) | Napthoquinone-type inhibitors of protein aggregation | |
ES2170104T3 (en) | INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS. | |
DE60336848D1 (en) | IMMUNOGENOUS AND CORRESPONDING ANTIBODIES SPECIFIC FOR COMMON HIGH-MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE | |
NO20011891L (en) | Use of radioligands for screening of inhibitors of amyloid <beta> peptide production | |
WO2002085285A3 (en) | Methods and reagents for regulating bone and cartilage formation | |
EA200200293A1 (en) | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | |
DE60224383D1 (en) | PROCEDURE FOR DETECTION IN YEAST TO INFLUENCE PROTEIN FOLDING | |
BR0314721A (en) | Tricyclic compounds useful for treating inflammatory and allergic disorders, processes for their preparation and pharmaceutical compositions containing them | |
DE69935133D1 (en) | ANTAGONIST FOR THE TREATMENT OF CD11 / CD18 ADHESION RECEPTOR-MEDIATED DISEASES | |
WO2007021886A3 (en) | Truncated memapsin 2 for use for treating alzheimer's disease | |
IL169889A0 (en) | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin | |
WO2002064618A3 (en) | Methods of identifying agents that mediate polypeptide aggregation | |
AR045004A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE 11-PIPERAZIN-1-ILDIBENZO [B, F] [1,4] TIAZEPINA | |
WO2004005882A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
WO2006042137A3 (en) | Methods for identifying parkinson's disease therapeutics | |
WO2000034511A3 (en) | Aβ-PEPTIDE SCREENING ASSAY | |
WO2004032975A3 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease | |
DE60034117D1 (en) | METHOD FOR PRODUCING GONADOTROPINE COMPOSITIONS | |
AU2002238766A1 (en) | Diagnostic screens for alzheimer's disease | |
CA2359357A1 (en) | Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances | |
WO2004035606A3 (en) | Bace binding peptides and uses thereof | |
EP1233075A3 (en) | BDNF polymorphism and association with bipolar disorder | |
DE602004024992D1 (en) | USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITES | |
WO2001049871A3 (en) | Process for finding a protease inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EC EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |